ArticleCell reports2023
MYC is a regulator of androgen receptor inhibition-induced metabolic requirements in prostate cancer.
Open access · goldAbstract read
In one paragraph
Article in Cell reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
6.5field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 25 citations in OpenAlex.
- A MYC family switch: L-MYC drives and maintains neuroendocrine lineage programs in prostate cancer.Neoplasia (New York, N.Y.) · 2026Article
- Mapping prostate cancer pathobiology: A review of genetically engineered mouse models (GEMMs).Gene · 2026Review
- Epigenetic and oncogenic inhibitors converge to drive a metabolic catastrophe in castration-resistant prostate cancer.The Journal of clinical investigation · 2026Article
- Review
- OGDHL Promotes Prostate Cancer Progression and Regulates Neuroendocrine Marker Expression and Nucleotide Abundance.Molecular cancer research : MCR · 2026Article
- Rewired lipid metabolism in castration-resistant prostate cancer: molecular interplay between glucose metabolism and sterol synthesis.Molecular biology reports · 2026Review
- Metformin in prostate cancer: a context-dependent antitumour strategy driven by metabolic vulnerability and signalling network.Discover oncology · 2026Review
- Cereblon (CRBN) inhibits prostate cancer metastasis by negatively regulating 6-phosphogluconate dehydrogenase (6PGD).Oncogene · 2026Article
- Alterations in AR-FOXA1 signaling in prostate cancer progression and therapeutic resistance.Journal of the National Cancer Center · 2026Review
- Identification and validation of critical mitochondrial hub genes for prostate cancer.Oncology letters · 2026Article
- Integrative transcriptomic profiling reveals subtype-specific therapeutic vulnerabilities and resistance mechanisms in prostate cancer.BMC cancer · 2026Article
- Primary Cilium Forces Neuroendocrine Shift in Prostate Cancer through YAP1 Repression and Reduced Mitochondrial Activity.Theranostics · 2026Article
- Cancer progression through the lens of age-induced metabolic reprogramming.Nature reviews. Cancer · 2025Review
- New frontiers in prostate cancer treatment from systemic therapy to targeted therapy.EMBO molecular medicine · 2025Review
- Single-Cell and Bulk RNA Sequencing Highlights Intra-Tumoral Heterogeneity and Malignant Progression Mechanisms in Prostate Cancer.Journal of cellular and molecular medicine · 2025Article
- Targeting Prostate Cancer Metabolism Through Transcriptional and Epigenetic Modulation: A Multi-Target Approach to Therapeutic Innovation.International journal of molecular sciences · 2025Review
- PGC-1α drives small cell neuroendocrine cancer progression toward an ASCL1-expressing subtype with increased mitochondrial capacity.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Metabolic adaptations in prostate cancer.British journal of cancer · 2024Review
- MED12 and CDK8/19 Modulate Androgen Receptor Activity and Enzalutamide Response in Prostate Cancer.Endocrinology · 2024Article
- Enzalutamide Sensitizes Castration-Resistant Prostate Cancer to Copper-Mediated Cell Death.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors at 6 institutions in 3 countries.
Preston D CrowellMolecular Biology Interdepartmental Program, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Jenna M GiafaglioneMolecular Biology Interdepartmental Program, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Anthony E JonesDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Nicholas M NunleyDepartment of Molecular, Cell, and Developmental Biology, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Takao HashimotoDepartment of Molecular, Cell, and Developmental Biology, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Amelie M L DelcourtDepartment of Molecular, Cell, and Developmental Biology, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Anton PetcherskiDivision of Endocrinology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Raag AgrawalJonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, CA 90095, USA; Department of Urology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA; Department of Human Genetics, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Matthew J BernardMolecular Biology Interdepartmental Program, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Johnny A DiazDepartment of Molecular, Cell, and Developmental Biology, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Kylie Y HeeringDepartment of Molecular, Cell, and Developmental Biology, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Rong Rong HuangDepartment of Pathology & Laboratory Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Jin-Yih LowDivision of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
Nedas MatulionisDepartment of Biological Chemistry, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Nora M NavoneDepartment of GU Medical Oncology, MD Anderson Cancer Center, Houston, TX 77030, USA.
Huihui YeDepartment of Pathology & Laboratory Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Amina ZoubeidiDepartment of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada; Vancouver Prostate Centre, Vancouver, BC, Canada.
Heather R ChristofkJonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, CA 90095, USA; Department of Biological Chemistry, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA; Eli and Edythe Broad Stem Cell Research Center, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Matthew B RettigDepartment of Urology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Robert E ReiterDepartment of Urology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Michael C HaffnerDivisions of Human Biology and Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA; Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA 98195, USA.
Paul C BoutrosJonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, CA 90095, USA; Department of Urology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA; Department of Human Genetics, University of California, Los Angeles, Los Angeles, CA 90095, USA; Institute for Precision Health, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Orian S ShirihaiDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA 90095, USA; Division of Endocrinology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA; Department of Clinical Biochemistry, School of Medicine, Ben Gurion University of The Negev, Beer-Sheva, Israel.
Ajit S DivakaruniDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Andrew S GoldsteinDepartment of Molecular, Cell, and Developmental Biology, University of California, Los Angeles, Los Angeles, CA 90095, USA; Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, CA 90095, USA; Department of Urology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA; Eli and Edythe Broad Stem Cell Research Center, University of California, Los Angeles, Los Angeles, CA 90095, USA; Molecular Biology Institute, University of California, Los Angeles, Los Angeles, CA 90095, USA. Electronic address: agoldstein@mednet.ucla.edu.
University of California, Los Angeles · USBen-Gurion University of the Negev · ILFred Hutch Cancer Center · USThe University of Texas MD Anderson Cancer Center · USUniversity of British Columbia · CAUniversity of Washington · US
Funding
UCLA Clinical and Translational Science InstituteUL1TR001881 · UNIVERSITY OF CALIFORNIA LOS ANGELES · 2025 to 2025
$9.9MUCLA SPORE IN PROSTATE CANCERP50CA092131 · UNIVERSITY OF CALIFORNIA LOS ANGELES · 2002 to 2005
$8.7MMEDICAL SCIENTIST TRAINING PROGRAMT32GM008042 · UNIVERSITY OF CALIFORNIA LOS ANGELES · 1985 to 2005
$6.0MRESEARCH TRAINING IN CELLULAR AND MOLECULAR BIOLOGYT32GM007185 · UNIVERSITY OF CALIFORNIA LOS ANGELES · 1985 to 2005
$5.7MDIGESTIVE DISEASE CENTERP30DK041301 · UNIVERSITY OF CALIFORNIA LOS ANGELES · 1990 to 2005
$5.2MTUMOR CELL SURFACES AND CHROMOSOMEST32CA009056 · UNIVERSITY OF CALIFORNIA LOS ANGELES · 1985 to 2025
$2.8MBiomedical Data Commons Workbench (BDCW)OT2OD030544 · OD · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Shankar Subramaniam · 2020 to 2020
$500kNetwork CoreU2CDK129496 · UNIVERSITY OF CALIFORNIA LOS ANGELES · 2025 to 2025
$460kUnderstanding How Metabolic Cofactors Control Cell Function and FateR35GM138003 · UNIVERSITY OF CALIFORNIA LOS ANGELES · 2025 to 2025
$423kTraining CoreTL1DK132768 · UNIVERSITY OF CALIFORNIA LOS ANGELES · 2025 to 2025
$390kNCATS NIH HHS UL1 TR001881NCI NIH HHS P50 CA092131NCI NIH HHS R01 CA237191NCI NIH HHS T32 CA009056NCI NIH HHS U01 CA224044NIDDK NIH HHS P30 DK041301NIDDK NIH HHS TL1 DK132768NIDDK NIH HHS U2C DK119886NIDDK NIH HHS U2C DK129496NIGMS NIH HHS R35 GM138003NIGMS NIH HHS T32 GM007185NIGMS NIH HHS T32 GM008042NIH HHS OT2 OD030544
Abstract
Advanced prostate cancers are treated with therapies targeting the androgen receptor (AR) signaling pathway. While many tumors initially respond to AR inhibition, nearly all develop resistance. It is critical to understand how prostate tumor cells respond to AR inhibition in order to exploit therapy-induced phenotypes prior to the outgrowth of treatment-resistant disease. Here, we comprehensively characterize the effects of AR blockade on prostate cancer metabolism using transcriptomics, metabolomics, and bioenergetics approaches. The metabolic response to AR inhibition is defined by reduced glycolysis, robust elongation of mitochondria, and increased reliance on mitochondrial oxidative metabolism. We establish DRP1 activity and MYC signaling as mediators of AR-blockade-induced metabolic phenotypes. Rescuing DRP1 phosphorylation after AR inhibition restores mitochondrial fission, while rescuing MYC restores glycolytic activity and prevents sensitivity to complex I inhibition. Our study provides insight into the regulation of treatment-induced metabolic phenotypes and vulnerabilities in prostate cancer.
Indexed as
Prostatic NeoplasmsProstatic Neoplasms, Castration-ResistantAndrogensCell Line, TumorHumansMaleProto-Oncogene Proteins c-mycReceptors, AndrogenSignal TransductionAndrogensProto-Oncogene Proteins c-mycReceptors, AndrogenCP: CancerCP: Metabolism
Identifiers
What Socratic holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.